Cooper T B
Analytical Psychopharmacology Division, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.
Psychiatr Q. 1996 Winter;67(4):297-311. doi: 10.1007/BF02326373.
Plasma level monitoring of clozapine and metabolites may prove beneficial in treating patients who show unusual drug metabolic activity. A threshold plasma level for patients who will respond to this medication is suggested. The interaction of gender, age, smoking, other medication and side effects with plasma clozapine and metabolites are discussed. Plasma level monitoring of clozapine and/or metabolites is recommended in patients who do not respond at usual therapeutic dose, who show untoward side effects at low dose or who are treated with other medications. Finally monitoring of patients who require more than 600 mg/day should be implemented because there is evidence that the incidence of seizures increases significantly above this dosage level. There is some evidence that high plasma clozapine levels are associated with seizures.
监测氯氮平及其代谢物的血浆水平可能有助于治疗那些药物代谢活动异常的患者。文中提出了对该药物有反应的患者的血浆水平阈值。讨论了性别、年龄、吸烟、其他药物以及副作用与血浆氯氮平及其代谢物之间的相互作用。对于在常规治疗剂量下无反应、在低剂量时出现不良副作用或正在接受其他药物治疗的患者,建议监测氯氮平及其代谢物的血浆水平。最后,对于每日剂量超过600毫克的患者应进行监测,因为有证据表明,超过此剂量水平癫痫发作的发生率会显著增加。有一些证据表明,高血浆氯氮平水平与癫痫发作有关。